Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net product revenue | 215,387 | 243,776 | 239,455 | NaN |
| Cost of product sold | 44,505 | 68,538 | 59,643 | NaN |
| Research and development | 35,018 | 41,935 | 37,704 | NaN |
| Sales and marketing | 29,899 | 27,693 | 28,055 | NaN |
| General and administrative | 20,398 | 45,079 | 16,774 | NaN |
| Depreciation and amortization | 5,968 | 7,432 | 5,968 | NaN |
| Stock-based compensation | 10,308 | 10,292 | 10,824 | NaN |
| Interest expense | 3,234 | 3,546 | 3,621 | NaN |
| Interest income | 5,757 | 5,854 | 26,410 | NaN |
| Income tax expense | 7,199 | 18,274 | 16,625 | NaN |
| Other segment items | 32,127 | 4,355 | 15,106 | NaN |
| Net income | 32,488 | 22,486 | 50,865 | 85,336 |
| Depreciation and impairment of long-lived assets | NaN | 1,490 | NaN | NaN |
| Depreciation | -13 | NaN | 7 | 13 |
| Intangible amortization | 5,961 | 5,962 | 5,961 | 11,922 |
| Acquired in-process research & development (ipr&d) expense | 32,000 | 4,250 | 15,000 | 15,000 |
| Stock-based compensation | 10,620 | 9,972 | 10,969 | 23,954 |
| Stock appreciation rights market adjustment | -312 | 320 | -145 | -110 |
| Debt issuance costs amortization | 151 | 157 | 161 | 329 |
| Deferred taxes | -3,863 | 7,376 | -3,881 | -10,796 |
| Amortization of premiums and accretion of discounts on investment securities | 220 | 281 | 336 | 904 |
| Other non-cash expenses | 560 | 402 | -9 | 932 |
| Trade receivables | 11,435 | -3,864 | 7,670 | 9,948 |
| Inventory | -76 | -1,525 | 782 | -1,098 |
| Prepaid expenses and other assets | 2,996 | -24,845 | -12,528 | 5,586 |
| Trade payables | 10,907 | -8,648 | -1,960 | 14,557 |
| Other liabilities | -46,184 | 52,451 | 28,026 | -12,483 |
| Purchase of property and equipment | NaN | 107 | 71 | 132 |
| Net cash provided by operating activities | 27,760 | 126,151 | 108,734 | 113,314 |
| Purchase of investment securities | 178,995 | 18,838 | 24,281 | 43,032 |
| Payment of milestones | NaN | 19,250 | NaN | NaN |
| Proceeds from maturities and sales of investment securities | 27,349 | 20,562 | 19,563 | 40,937 |
| Payment of upfront fee related to license agreements | 32,000 | 0 | 0 | 15,000 |
| Net cash (used in) provided by investing activities | -183,646 | -17,633 | -4,789 | -17,227 |
| Principal repayment of long-term debt | 5,000 | 5,000 | 3,750 | 7,500 |
| Payments of employee withholding taxes related to stock-based awards | 2,565 | 663 | 0 | 2,341 |
| Proceeds from exercised options | 347 | 2,648 | 754 | 6,803 |
| Net cash used in financing activities | -7,218 | -3,015 | -2,996 | -3,038 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -163,104 | 105,503 | 100,949 | 93,049 |
| Cash, cash equivalents, and restricted cash-beginning of period | 752,772 | -193,998 | 453,271 | NaN |
| Cash, cash equivalents, and restricted cash-end of period | 589,668 | 105,503 | 647,269 | NaN |